Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn’s disease

Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn’s disease

Background: Since not all Crohn’s disease (CD) patients respond adequately to ustekinumab therapy, biomarkers could aid to monitor treatment response and optimize therapeutic outcomes. Objectives: To explore the dynamics of serum biomarker concentrations to monitor the response to ustekinumab treatm...

Full description

Bibliographic Details
Main Authors:	Nathalie Van den Berghe, Dahham Alsoud, Bram Verstockt, Séverine Vermeire, Paul Declerck, Debby Thomas
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-08-01
Series:	Therapeutic Advances in Gastroenterology
Online Access:	https://doi.org/10.1177/17562848231189110

Similar Items

Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises
by: Dahham Alsoud, et al.
Published: (2022-01-01)

Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model
by: Jurij Aguiar Zdovc, et al.
Published: (2021-09-01)

Ustekinumab and remission in perianal Crohn's disease: A case report
by: C.E. Alcántara-Figueroa, et al.
Published: (2023-10-01)

Integrated analysis of microbe-host interactions in Crohn’s disease reveals potential mechanisms of microbial proteins on host gene expression
by: Padhmanand Sudhakar, et al.
Published: (2022-05-01)

Long-term real-world data of ustekinumab in Crohn’s disease: the Stockholm ustekinumab study
by: Francesca Bello, et al.
Published: (2024-04-01)

Intensification with Intravenous Ustekinumab in Refractory Crohn’s Disease
by: Cristina Suárez Ferrer, et al.
Published: (2024-01-01)

Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
by: María Chaparro, et al.
Published: (2022-08-01)

Clinical Advances in Ustekinumab in the Treatment of Crohn's Disease
by: Xin ZHAO, Yingde WANG
Published: (2022-09-01)

Ustekinumab in patients with Crohn’s disease with extraintestinal manifestations (psoriasis)
by: P. A. Makarchuk, et al.
Published: (2020-10-01)

Long-term follow-up of the red density pilot trial: a basis for long-term prediction of sustained clinical remission in ulcerative colitis?
by: Pieter Sinonquel, et al.
Published: (2023-09-01)

USTEKINUMAB IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN OBSERVATIONAL STUDY
by: Paula Cenira Senger de CASTRO, et al.
Published: (2022-11-01)

Refractory metastatic Crohn’s disease responsive to ustekinumab dose intensification
by: Teresa L. Xiao, BA, et al.
Published: (2023-02-01)

High Immunogenicity to Influenza Vaccination in Crohn’s Disease Patients Treated with Ustekinumab
by: Laura Doornekamp, et al.
Published: (2020-08-01)

Ustekinumab is associated with superior treatment persistence but not with higher remission rates vedolizumab in patients with refractory Crohn’s disease: results from a multicentre cohort study
by: Péter Bacsur, et al.
Published: (2022-12-01)

Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
by: Séverine Vermeire, et al.
Published: (2023-11-01)

Response to Ustekinumab Therapy Is Associated with an Improvement of Nutritional Status in Patients with Crohn’s Disease
by: Lorenzo Bertani, et al.
Published: (2023-09-01)

Ustekinumab in the treatment of acute disseminated pyoderma gangrenosum in a patient with Crohn’s disease
by: Klaudia Miklusiak, et al.
Published: (2023-05-01)

Ultrasound remission after biologic induction and long-term endoscopic remission in Crohn's disease: a prospective cohort studyResearch in context
by: Mariangela Allocca, et al.
Published: (2024-05-01)

Let Food Be Thy Medicine—Its Role in Crohn’s Disease
by: Judith Wellens, et al.
Published: (2021-03-01)

SAPHO Syndrome in Crohn’s Disease Successfully Treated with Ustekinumab: Case Report and Review of the Literature
by: Sara Caporuscio, et al.
Published: (2023-11-01)

A bibliometric and visual analysis of the use of ustekinumab in Crohn’s disease using CiteSpace
by: Yi Chen, et al.
Published: (2024-01-01)

The Efficacy of Combination Therapy with Ustekinumab and Budesonide for Crohn’s Disease: A Randomized Controlled Trial
by: Rintaro Moroi, et al.
Published: (2023-11-01)

Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn’s disease
by: Jiayin Yao, et al.
Published: (2023-07-01)

Real clinical practice of complicated Crohn’s disease treatment with ustekinumab: clinical case presentation
by: P. A. Makarchuk, et al.
Published: (2022-05-01)

Machine learning gene expression predicting model for ustekinumab response in patients with Crohn's disease
by: Manrong He, et al.
Published: (2021-12-01)

Ustekinumab
by: Murat Borlu
Published: (2022-04-01)

Use of double-balloon endoscopy and an endoscopic scoring system to assess endoscopic remission in isolated small bowel Crohn’s disease after treatment with infliximab
by: Wei Han, et al.
Published: (2024-01-01)

Effectiveness and safety of ustekinumab in bio-naïve Crohn’s disease patients: a multicentre observational retrospective study
by: Valdés Delgado Teresa, et al.
Published: (2023-02-01)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
by: Kira L. Newman, et al.
Published: (2023-03-01)

Effectiveness of Crohn’s Disease Exclusion Diet for Induction of Remission in Crohn’s Disease Adult Patients
by: Martyna Szczubełek, et al.
Published: (2021-11-01)

Probiotics in Crohn's disease remission: a systematic review
by: Kamilla Pontes Azevedo, et al.
Published: (2022-03-01)

Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis
by: Ho-Su Lee, et al.
Published: (2020-07-01)

IM-UNITI at three years: Stellar Stelara® or stardust? The efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's disease
by: Travis, S
Published: (2019)

Ustekinumab in pediatric patients with Crohn’s disease: safety, and efficacy results from a multicenter retrospective study in China
by: Ping Li, et al.
Published: (2024-04-01)

Ustekinumab y remisión en enfermedad de Crohn con compromiso perianal: reporte de un caso
by: C.E. Alcántara-Figueroa, et al.
Published: (2023-10-01)

Effectiveness and Safety of Ustekinumab for Moderate to Severely Active Crohn’s Disease: Results from an Early Access Program in Brazil
by: Julio Maria Fonseca Chebli, et al.
Published: (2022-10-01)

Ustekinumab Promotes Radiological Fistula Healing in Perianal Fistulizing Crohn’s Disease: A Retrospective Real-World Analysis
by: Jiayin Yao, et al.
Published: (2023-01-01)

Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
by: Michelle Vu, et al.
Published: (2023-03-01)

Early transmural healing and its predictors assessed by magnetic resonance enterography in patients with Crohn’s disease receiving ustekinumab
by: Longyuan Zhou, et al.
Published: (2023-05-01)

Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy
by: Roberto Ravasio, et al.
Published: (2023-01-01)